Danish biotech firm launches DNA chip  

2006.07.12
Medical Prognosis Institute has launched a DNA chip in Denmark to help finance MPI's development of a DNA chip for cancer diagnosis

Medical Prognosis Institute (MPI), a Danish biotech firm based in Hørsholm north of Copenhagen, has launched a DNA chip in Denmark to help finance MPI's development of a DNA chip for cancer diagnosis. The AmpliChip has been developed by Roche Diagnostics, and is the first DNA chip approved for diagnostic use in Europe and the US. The AmpliChip can help in tailoring medication to patients.

The Danish firm aims to develop a DNA chip based on the same principle as the AmpliChip. MPI's chip is targeted for cancer diagnosis and prognosis. By means of DNA microchip technology, a sample of tumour tissue can be analysed and from this, it can be predicted whether or not a cancer patient has been cured by primary surgery.

MPI plans to test its cancer chips on patients this summer. The trials will last 2 years, and if successful, the firm expects to market the chips in three years. The capital for testing and marketing will come from selling the AmpliChip, from public funds, private investors and an IPO on First North, a Copenhagen Stock Exchange market place for SMEs seeking expansion and development.

Steen Knudsen, research director of MPI says: "We are currently working on becoming a stock exchange listed company, and the objective is to raise a multimillion sum." The news was reported by financial daily newspaper Børsen.

Link > MPI 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×